Cargando…

Somatotropic Axis Dysfunction in Non-Alcoholic Fatty Liver Disease: Beneficial Hepatic and Systemic Effects of Hormone Supplementation

Background: Somatotropic axis dysfunction associated with non-alcoholic fatty liver disease (NAFLD) has potential multisystemic detrimental effects. Here, we analysed the effects of growth hormone (GH) and insulin-like growth factor-1 (IGF-1) supplementation on liver histology, adipokine profile and...

Descripción completa

Detalles Bibliográficos
Autores principales: Cabrera, Daniel, Cabello-Verrugio, Claudio, Solís, Nancy, San Martín, Diego, Cofré, Catalina, Pizarro, Margarita, Arab, Juan Pablo, Abrigo, Johanna, Campos, Fabián, Irigoyen, Betzabé, Carrasco-Avino, Gonzalo, Bezares, Katiuska, Riquelme, Valentina, Riquelme, Arnoldo, Arrese, Marco, Barrera, Francisco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983806/
https://www.ncbi.nlm.nih.gov/pubmed/29724029
http://dx.doi.org/10.3390/ijms19051339
_version_ 1783328504031477760
author Cabrera, Daniel
Cabello-Verrugio, Claudio
Solís, Nancy
San Martín, Diego
Cofré, Catalina
Pizarro, Margarita
Arab, Juan Pablo
Abrigo, Johanna
Campos, Fabián
Irigoyen, Betzabé
Carrasco-Avino, Gonzalo
Bezares, Katiuska
Riquelme, Valentina
Riquelme, Arnoldo
Arrese, Marco
Barrera, Francisco
author_facet Cabrera, Daniel
Cabello-Verrugio, Claudio
Solís, Nancy
San Martín, Diego
Cofré, Catalina
Pizarro, Margarita
Arab, Juan Pablo
Abrigo, Johanna
Campos, Fabián
Irigoyen, Betzabé
Carrasco-Avino, Gonzalo
Bezares, Katiuska
Riquelme, Valentina
Riquelme, Arnoldo
Arrese, Marco
Barrera, Francisco
author_sort Cabrera, Daniel
collection PubMed
description Background: Somatotropic axis dysfunction associated with non-alcoholic fatty liver disease (NAFLD) has potential multisystemic detrimental effects. Here, we analysed the effects of growth hormone (GH) and insulin-like growth factor-1 (IGF-1) supplementation on liver histology, adipokine profile and muscle function in an NAFLD model. Methods: C57BL/6 mice were fed with a high fat diet (HFD) for 12 weeks and were separated into three groups treated for 4 weeks with: (1) High fat diet (HFD) (n = 10); (2) HFD + GH 9 μg/g/d (n = 10); (3) HFD + IGF-1 0.02 µg/g/d (n = 9). A control group fed a chow diet was included (n = 6). Liver histology, liver triglycerides content, serum alanine aminotransferase (ALT) activity, adiponectin and leptin serum levels, in vivo muscle strength, tetanic force and muscle fibre cross-sectional area (CSA) were measured. Results: HFD + GH and HFD + IGF-1 groups showed significantly lower ALT activity compared to HFD (p < 0.01). Liver triglyceride content in HFD + GH was decreased compared to HFD (p < 0.01). Histologic steatosis score was increased in HFD and HFD + GH group (p < 0.01), whereas HFD + IGF-1 presented no difference compared to the chow group (p = 0.3). HFD + GH group presented lower serum leptin and adiponectin levels compared to HFD. GH and IGF-1 supplementation therapy reverted HFD-induced reduction in muscle strength and CSA (sarcopenia). Conclusions: GH and IGF-1 supplementation induced significant improvement in liver steatosis, aminotransferases and sarcopenia in a diet-induced NAFLD model.
format Online
Article
Text
id pubmed-5983806
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-59838062018-06-05 Somatotropic Axis Dysfunction in Non-Alcoholic Fatty Liver Disease: Beneficial Hepatic and Systemic Effects of Hormone Supplementation Cabrera, Daniel Cabello-Verrugio, Claudio Solís, Nancy San Martín, Diego Cofré, Catalina Pizarro, Margarita Arab, Juan Pablo Abrigo, Johanna Campos, Fabián Irigoyen, Betzabé Carrasco-Avino, Gonzalo Bezares, Katiuska Riquelme, Valentina Riquelme, Arnoldo Arrese, Marco Barrera, Francisco Int J Mol Sci Article Background: Somatotropic axis dysfunction associated with non-alcoholic fatty liver disease (NAFLD) has potential multisystemic detrimental effects. Here, we analysed the effects of growth hormone (GH) and insulin-like growth factor-1 (IGF-1) supplementation on liver histology, adipokine profile and muscle function in an NAFLD model. Methods: C57BL/6 mice were fed with a high fat diet (HFD) for 12 weeks and were separated into three groups treated for 4 weeks with: (1) High fat diet (HFD) (n = 10); (2) HFD + GH 9 μg/g/d (n = 10); (3) HFD + IGF-1 0.02 µg/g/d (n = 9). A control group fed a chow diet was included (n = 6). Liver histology, liver triglycerides content, serum alanine aminotransferase (ALT) activity, adiponectin and leptin serum levels, in vivo muscle strength, tetanic force and muscle fibre cross-sectional area (CSA) were measured. Results: HFD + GH and HFD + IGF-1 groups showed significantly lower ALT activity compared to HFD (p < 0.01). Liver triglyceride content in HFD + GH was decreased compared to HFD (p < 0.01). Histologic steatosis score was increased in HFD and HFD + GH group (p < 0.01), whereas HFD + IGF-1 presented no difference compared to the chow group (p = 0.3). HFD + GH group presented lower serum leptin and adiponectin levels compared to HFD. GH and IGF-1 supplementation therapy reverted HFD-induced reduction in muscle strength and CSA (sarcopenia). Conclusions: GH and IGF-1 supplementation induced significant improvement in liver steatosis, aminotransferases and sarcopenia in a diet-induced NAFLD model. MDPI 2018-05-02 /pmc/articles/PMC5983806/ /pubmed/29724029 http://dx.doi.org/10.3390/ijms19051339 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Cabrera, Daniel
Cabello-Verrugio, Claudio
Solís, Nancy
San Martín, Diego
Cofré, Catalina
Pizarro, Margarita
Arab, Juan Pablo
Abrigo, Johanna
Campos, Fabián
Irigoyen, Betzabé
Carrasco-Avino, Gonzalo
Bezares, Katiuska
Riquelme, Valentina
Riquelme, Arnoldo
Arrese, Marco
Barrera, Francisco
Somatotropic Axis Dysfunction in Non-Alcoholic Fatty Liver Disease: Beneficial Hepatic and Systemic Effects of Hormone Supplementation
title Somatotropic Axis Dysfunction in Non-Alcoholic Fatty Liver Disease: Beneficial Hepatic and Systemic Effects of Hormone Supplementation
title_full Somatotropic Axis Dysfunction in Non-Alcoholic Fatty Liver Disease: Beneficial Hepatic and Systemic Effects of Hormone Supplementation
title_fullStr Somatotropic Axis Dysfunction in Non-Alcoholic Fatty Liver Disease: Beneficial Hepatic and Systemic Effects of Hormone Supplementation
title_full_unstemmed Somatotropic Axis Dysfunction in Non-Alcoholic Fatty Liver Disease: Beneficial Hepatic and Systemic Effects of Hormone Supplementation
title_short Somatotropic Axis Dysfunction in Non-Alcoholic Fatty Liver Disease: Beneficial Hepatic and Systemic Effects of Hormone Supplementation
title_sort somatotropic axis dysfunction in non-alcoholic fatty liver disease: beneficial hepatic and systemic effects of hormone supplementation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983806/
https://www.ncbi.nlm.nih.gov/pubmed/29724029
http://dx.doi.org/10.3390/ijms19051339
work_keys_str_mv AT cabreradaniel somatotropicaxisdysfunctioninnonalcoholicfattyliverdiseasebeneficialhepaticandsystemiceffectsofhormonesupplementation
AT cabelloverrugioclaudio somatotropicaxisdysfunctioninnonalcoholicfattyliverdiseasebeneficialhepaticandsystemiceffectsofhormonesupplementation
AT solisnancy somatotropicaxisdysfunctioninnonalcoholicfattyliverdiseasebeneficialhepaticandsystemiceffectsofhormonesupplementation
AT sanmartindiego somatotropicaxisdysfunctioninnonalcoholicfattyliverdiseasebeneficialhepaticandsystemiceffectsofhormonesupplementation
AT cofrecatalina somatotropicaxisdysfunctioninnonalcoholicfattyliverdiseasebeneficialhepaticandsystemiceffectsofhormonesupplementation
AT pizarromargarita somatotropicaxisdysfunctioninnonalcoholicfattyliverdiseasebeneficialhepaticandsystemiceffectsofhormonesupplementation
AT arabjuanpablo somatotropicaxisdysfunctioninnonalcoholicfattyliverdiseasebeneficialhepaticandsystemiceffectsofhormonesupplementation
AT abrigojohanna somatotropicaxisdysfunctioninnonalcoholicfattyliverdiseasebeneficialhepaticandsystemiceffectsofhormonesupplementation
AT camposfabian somatotropicaxisdysfunctioninnonalcoholicfattyliverdiseasebeneficialhepaticandsystemiceffectsofhormonesupplementation
AT irigoyenbetzabe somatotropicaxisdysfunctioninnonalcoholicfattyliverdiseasebeneficialhepaticandsystemiceffectsofhormonesupplementation
AT carrascoavinogonzalo somatotropicaxisdysfunctioninnonalcoholicfattyliverdiseasebeneficialhepaticandsystemiceffectsofhormonesupplementation
AT bezareskatiuska somatotropicaxisdysfunctioninnonalcoholicfattyliverdiseasebeneficialhepaticandsystemiceffectsofhormonesupplementation
AT riquelmevalentina somatotropicaxisdysfunctioninnonalcoholicfattyliverdiseasebeneficialhepaticandsystemiceffectsofhormonesupplementation
AT riquelmearnoldo somatotropicaxisdysfunctioninnonalcoholicfattyliverdiseasebeneficialhepaticandsystemiceffectsofhormonesupplementation
AT arresemarco somatotropicaxisdysfunctioninnonalcoholicfattyliverdiseasebeneficialhepaticandsystemiceffectsofhormonesupplementation
AT barrerafrancisco somatotropicaxisdysfunctioninnonalcoholicfattyliverdiseasebeneficialhepaticandsystemiceffectsofhormonesupplementation